BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mathew EN, Berry BC, Yang HW, Carroll RS, Johnson MD. Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints. Int J Mol Sci 2022;23:1711. [PMID: 35163633 DOI: 10.3390/ijms23031711] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Badkas A, De Landtsheer S, Sauter T. Expanding the Disease Network of Glioblastoma Multiforme via Topological Analysis. IJMS 2023;24:3075. [DOI: 10.3390/ijms24043075] [Reference Citation Analysis]
2 Allami P, Heidari A, Rezaei N. The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. Front Mol Biosci 2022;9:1083645. [PMID: 36660431 DOI: 10.3389/fmolb.2022.1083645] [Reference Citation Analysis]
3 El Atat O, Naser R, Abdelkhalek M, Habib RA, El Sibai M. Molecular targeted therapy: A new avenue in glioblastoma treatment. Oncol Lett 2023;25:46. [PMID: 36644133 DOI: 10.3892/ol.2022.13632] [Reference Citation Analysis]
4 Ruiz-Molina D, Mao X, Alfonso-Triguero P, Lorenzo J, Bruna J, Yuste VJ, Candiota AP, Novio F. Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? Cancers (Basel) 2022;14:4960. [PMID: 36230883 DOI: 10.3390/cancers14194960] [Reference Citation Analysis]
5 Karami Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, Alizadeh SD, Pourghasem Z, Abbasi Oshagh P, Azargoonjahromi A, Almasi F, Manzoor HZ, Khalesi B, Pourzardosht N, Khalili S, Payandeh Z. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. Vaccines (Basel) 2022;10:1448. [PMID: 36146527 DOI: 10.3390/vaccines10091448] [Reference Citation Analysis]
6 Bobholz SA, Lowman AK, Connelly JM, Duenweg SR, Winiarz A, Brehler M, Kyereme F, Cochran EJ, Coss D, Ellingson BM, Mueller WM, Agarwal M, Banerjee A, Laviolette PS. Non-invasive tumor probability maps developed using autopsy tissue identify novel areas of tumor beyond the imaging-defined margin.. [DOI: 10.1101/2022.08.17.22278910] [Reference Citation Analysis]
7 Nakagawa-saito Y, Saitoh S, Mitobe Y, Sugai A, Togashi K, Suzuki S, Kitanaka C, Okada M. HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny. IJMS 2022;23:8084. [DOI: 10.3390/ijms23158084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lechpammer M, Rao R, Shah S, Mirheydari M, Bhattacharya D, Koehler A, Toukam DK, Haworth KJ, Pomeranz Krummel D, Sengupta S. Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers. Cancers (Basel) 2022;14:1627. [PMID: 35406398 DOI: 10.3390/cancers14071627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]